Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine

K. J. Lee, N. Y. Kim, J. K. Kwon, K. C. Huh, O. Y. Lee, J. S. Lee, S. C. Choi, C. I. Sohn, S. J. Myung, H. J. Park, M. K. Choi, Young-Tae Bak, P. L. Rhee

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background The 5-HT 3 receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT 3 receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). Methods This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5μg once daily or a 4-week treatment of mebeverine 135mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. Key Results The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. Conclusions & Inferences Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.

Original languageEnglish
Pages (from-to)1098-1104
Number of pages7
JournalNeurogastroenterology and Motility
Volume23
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Randomized Controlled Trials
Serotonin Receptors
Abdominal Pain
Therapeutics
Ischemic Colitis
Safety
Constipation
Habits
ramosetron
mebeverine

Keywords

  • 5-HT receptor antagonist
  • Irritable bowel syndrome
  • Mebeverine
  • Ramosetron
  • Rome III criteria

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology

Cite this

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea : A multicenter, randomized clinical trial, compared with mebeverine. / Lee, K. J.; Kim, N. Y.; Kwon, J. K.; Huh, K. C.; Lee, O. Y.; Lee, J. S.; Choi, S. C.; Sohn, C. I.; Myung, S. J.; Park, H. J.; Choi, M. K.; Bak, Young-Tae; Rhee, P. L.

In: Neurogastroenterology and Motility, Vol. 23, No. 12, 01.12.2011, p. 1098-1104.

Research output: Contribution to journalArticle

Lee, KJ, Kim, NY, Kwon, JK, Huh, KC, Lee, OY, Lee, JS, Choi, SC, Sohn, CI, Myung, SJ, Park, HJ, Choi, MK, Bak, Y-T & Rhee, PL 2011, 'Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine', Neurogastroenterology and Motility, vol. 23, no. 12, pp. 1098-1104. https://doi.org/10.1111/j.1365-2982.2011.01771.x
Lee, K. J. ; Kim, N. Y. ; Kwon, J. K. ; Huh, K. C. ; Lee, O. Y. ; Lee, J. S. ; Choi, S. C. ; Sohn, C. I. ; Myung, S. J. ; Park, H. J. ; Choi, M. K. ; Bak, Young-Tae ; Rhee, P. L. / Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea : A multicenter, randomized clinical trial, compared with mebeverine. In: Neurogastroenterology and Motility. 2011 ; Vol. 23, No. 12. pp. 1098-1104.
@article{97720fbdf3b84a9cbd4340ba3dcfe39c,
title = "Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine",
abstract = "Background The 5-HT 3 receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT 3 receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). Methods This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5μg once daily or a 4-week treatment of mebeverine 135mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. Key Results The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37{\%}vs 38{\%} on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. Conclusions & Inferences Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.",
keywords = "5-HT receptor antagonist, Irritable bowel syndrome, Mebeverine, Ramosetron, Rome III criteria",
author = "Lee, {K. J.} and Kim, {N. Y.} and Kwon, {J. K.} and Huh, {K. C.} and Lee, {O. Y.} and Lee, {J. S.} and Choi, {S. C.} and Sohn, {C. I.} and Myung, {S. J.} and Park, {H. J.} and Choi, {M. K.} and Young-Tae Bak and Rhee, {P. L.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1365-2982.2011.01771.x",
language = "English",
volume = "23",
pages = "1098--1104",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea

T2 - A multicenter, randomized clinical trial, compared with mebeverine

AU - Lee, K. J.

AU - Kim, N. Y.

AU - Kwon, J. K.

AU - Huh, K. C.

AU - Lee, O. Y.

AU - Lee, J. S.

AU - Choi, S. C.

AU - Sohn, C. I.

AU - Myung, S. J.

AU - Park, H. J.

AU - Choi, M. K.

AU - Bak, Young-Tae

AU - Rhee, P. L.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background The 5-HT 3 receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT 3 receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). Methods This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5μg once daily or a 4-week treatment of mebeverine 135mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. Key Results The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. Conclusions & Inferences Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.

AB - Background The 5-HT 3 receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT 3 receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). Methods This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5μg once daily or a 4-week treatment of mebeverine 135mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. Key Results The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. Conclusions & Inferences Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.

KW - 5-HT receptor antagonist

KW - Irritable bowel syndrome

KW - Mebeverine

KW - Ramosetron

KW - Rome III criteria

UR - http://www.scopus.com/inward/record.url?scp=81855185606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855185606&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2011.01771.x

DO - 10.1111/j.1365-2982.2011.01771.x

M3 - Article

C2 - 21920001

AN - SCOPUS:81855185606

VL - 23

SP - 1098

EP - 1104

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 12

ER -